Literature DB >> 115675

Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals.

Y Masuda, Y Utsui, Y Shiraishi, T Karasawa, K Yoshida, M Shimizu.   

Abstract

The relationships between plasma concentrations of diphenylhydantoin (DPH), phenobarbital (PB), carbamazepine (CBZ), and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant and neurotoxic effects were studied in various species of animals. Anticonvulsant activities of test drugs were examined by the maximal electroshock seizure (MES) test. Neurotoxicities were determined by the rotorod performance test in mice and rats and by behavioral observations in rabbits, dogs, and monkeys. It was demonstrated that both the anticonvulsant effects and the neurotoxic effects of the drugs tested were more closely correlated with their plasma concentrations than with the dosages administered. There was a critical plasma concentration for each drug to show an anticonvulsant effect or to cause a neurotoxic effect in an individual animal. The critical plasma concentrations for anticonvulsant and neurotoxic effects of each drug were relatively constant among different species, with the exception of DPH in rabbits, which had twice the value in other species. The therapeutic ranges of plasma concentrations of DPH, PB, and CBZ determined in various species of animals coincided well with those recommended clinically. AD-810 was found to be effective against MES without signs of neurological toxicity in the ranges of plasma concentrations of 9.8 to 74.0, 10.8 to 95.0, 9.6 to 117.0, and 12.6 to 96.2 microgram/ml in mice, rats, rabbits, and dogs, respectively. These results seem to suggest that AD-810 may be effective clinically at plasma concentrations above 10 microgram/ml, with a therapeutic range up to 70 microgram/ml, which is much wider than the therapeutic ranges of DPH (10--20 microgram/ml), PB (10--30 microgram/ml), and CBZ (4--10 microgram/ml).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 115675     DOI: 10.1111/j.1528-1157.1979.tb04846.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  17 in total

1.  Effect of lamotrigine and carbamazepine on corticotropin-releasing factor-associated serotonergic transmission in rat dorsal raphe nucleus.

Authors:  Shunske Tanahashi; Satoshi Yamamura; Masanori Nakagawa; Eishi Motomura; Motohiro Okada
Journal:  Psychopharmacology (Berl)       Date:  2011-09-27       Impact factor: 4.530

2.  Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse.

Authors:  Mitsuo Tanabe; Akiko Sakaue; Keiko Takasu; Motoko Honda; Hideki Ono
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-10-22       Impact factor: 3.000

3.  Proceedings of the British Pharmacological Society. 10th-12th September, 1980. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1981-03       Impact factor: 8.739

4.  Pharmacological discrimination between effects of carbamazepine on hippocampal basal, Ca(2+)- and K(+)-evoked serotonin release.

Authors:  Y Kawata; M Okada; T Murakami; A Kamata; G Zhu; S Kaneko
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

5.  Effect of chronic administration of phenytoin on regional monoamine levels in rat brain.

Authors:  M H Meshkibaf; M N Subhash; K M Lakshmana; B S Rao
Journal:  Neurochem Res       Date:  1995-07       Impact factor: 3.996

6.  HPLC method for simultaneous determination of impurities and degradation products in zonisamide.

Authors:  E K S Vijayakumar; D M Dhore; M Kumar
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

7.  Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum.

Authors:  P C Waldmeier; P Martin; K Stöcklin; C Portet; M Schmutz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

8.  Zonisamide decreases ethanol intake in rats and mice.

Authors:  Clifford M Knapp; Melissa Mercado; Tara Lynn Markley; Steven Crosby; Domenic A Ciraulo; Conan Kornetsky
Journal:  Pharmacol Biochem Behav       Date:  2007-04-11       Impact factor: 3.533

9.  Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse.

Authors:  H Iven; E Feldbusch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

10.  Zonisamide - a review of experience and use in partial seizures.

Authors:  Angus A Wilfong; L James Willmore
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.